Monoclonal antibody therapeutics with up to five specificities Functional enhancement through fusion of target-specific peptides

mAbs

Volumn 5, Issue 2, 2013, Pages 208-218

  LaFleur, David W ^a   Abramyan, Donara ^a   Kanakaraj, Palanisamy ^a   Smith, Rodger G ^a   Shah, Rutul R ^a   Wang, Geping ^a   Yao, Xiao Tao ^a   Kankanala, Spandana ^a   Boyd, Ernie ^a   Zaritskaya, Liubov ^a   Nam, Viktoriya ^a   Puffer, Bridget A ^a   Buasen, Pete ^a   Kaithamana, Shashi ^a   Burnette, Andrew F ^a   Krishnamurthy, Rajesh ^a   Patel, Dimki ^a   Roschke, Viktor V ^a   Kiener, Peter A ^a   Hilbert, David M ^a   Barbas III, Carlos F ^a,b   more..

^a Zyngenia Inc   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antibody engineering; Multi specific antibody

Indexed keywords

ADALIMUMAB; ANGIOPOIETIN 2; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PALIVIZUMAB; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANTIBODY ENGINEERING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEK293; CELL STRAIN MCF 7; COMBINATORIAL LIBRARY; LIGHT CHAIN; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANTIBODY ENGINEERING; MULTI-SPECIFIC ANTIBODY;

AMINO ACID SEQUENCE; ANGIOPOIETIN-2; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY SPECIFICITY; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876336136     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.23043     Document Type: Article

References (38)

1. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al.; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-40; PMID:22257673; http://dx.doi.org/10.1016/S0140- 6736(11)61847-3
2. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa1113216
3. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21: 484-90; PMID:14573361; http://dx.doi.org/10.1016/j.tibtech.2003.08.007
4. Koide A, Bailey CW, Huang X, Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 1998; 284: 1141-51; PMID:9837732; http://dx.doi.org/10.1006/jmbi.1998.2238
5. Nord K, Nilsson J, Nilsson B, Uhlén M, Nygren PA. A combinatorial library of an α-helical bacterial receptor domain. Protein Eng 1995; 8: 601-8; PMID:8532685; http://dx.doi.org/10.1093/protein/8.6.601
6. Reusch U, Le Gall F, Hensel M, Moldenhauer G, Ho AD, Little M, et al. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Int J Cancer 2004; 112: 509-18; PMID:15382079; http://dx.doi.org/10.1002/ ijc.20417
7. Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323: 1610-4; PMID:19299620; http://dx.doi.org/10. 1126/science.1165480
8. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25: 1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
9. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010; 23: 289-97; PMID:20150180; http://dx.doi.org/10.1093/protein/ gzq005
10. Gavrilyuk JI, Wuellner U, Salahuddin S, Goswami RK, Sinha SC, Barbas CF, 3rd. An efficient chemical approach to bispecific antibodies and antibodies of high valency. Bioorg Med Chem Lett 2009; 19: 3716-20; PMID:19497743; http://dx.doi.org/10.1016/j. bmcl.2009.05.047
11. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155: 219-25; PMID:7602098
12. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9: 617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/ 9.7.617
13. Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 2011; 108: 11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
14. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285: 19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc. M110.117382
15. Kanakaraj P, Puffer BA, Yao XT, Kankanala S, Boyd E, Shah RR, et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 2012; 4: 600-13; PMID:22864384; http://dx.doi.org/10.4161/ mabs.21227
16. Kimura RH, Cheng Z, Gambhir SS, Cochran Jr. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 2009; 69: 2435-42; PMID:19276378; http://dx.doi.org/10.1158/0008-5472.CAN- 08-2495
17. Backliwal G, Hildinger M, Chenuet S, Wulhfard S, De Jesus M, Wurm FM. Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res 2008; 36:e96; PMID:18617574; http://dx.doi.org/10.1093/nar/gkn423
18. Li J, Lundberg E, Vernet E, Larsson B, Höidén- Guthenberg I, Gräslund T. Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. Biotechnol Appl Biochem 2010; 55: 99-109; PMID:20088825
19. Göstring L, Chew MT, Orlova A, Höidén-Guthenberg I, Wennborg A, Carlsson J, et al. Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. Int J Oncol 2010; 36: 757-63; PMID:20198317; http://dx.doi.org/10.3892/ ijo-00000551
20. Chakraborty AK, Liang K, DiGiovanna MP. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 2008; 68: 1538-45; PMID:18316619; http://dx.doi.org/10.1158/0008-5472.CAN-07-5935
21. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007; 97: 453-7; PMID:17667926; http://dx.doi.org/10.1038/sj.bjc.6603910
22. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11: 582-93; PMID:22248472; http://dx.doi.org/10.1158/1535- 7163.MCT-11-0820
23. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20: 472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
24. Kronqvist N, Malm M, Göstring L, Gunneriusson E, Nilsson M, Höidén Guthenberg I, et al. Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel 2011; 24: 385-96; PMID:21177282; http://dx.doi.org/10.1093/protein/ gzq118
25. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-85; PMID:20651738; http://dx.doi.org/10.1038/nrc2894
26. Shimamoto G, Gegg C, Boone T, Quéva C. Peptibodies: A flexible alternative format to antibodies. MAbs 2012; 4: 586-91; PMID:22820181; http://dx.doi.org/10.4161/mabs.21024
27. Singh H, Raghava GP. ProPred: prediction of HLADR binding sites. Bioinformatics 2001; 17: 1236-7; PMID:11751237; http://dx.doi.org/10.1093/ bioinformatics/ 17.12.1236
28. Perry LC, Jones TD, Baker MP. New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D 2008; 9: 385-96; PMID:18989990; http://dx.doi.org/10.2165/0126839-200809060- 00004
29. Bryson CJ, Jones TD, Baker MP. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs 2010; 24: 1-8; PMID:20055528; http://dx.doi.org/10.2165/11318560-000000000- 00000
30. Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 2007; 124: 26-32; PMID:17490912; http://dx.doi.org/10.1016/j. clim.2007.03.544
31. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26; PMID:11821453; http://dx.doi.org/10.1200/JCO.20.3.719
32. Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13: 485-98; PMID:19034632; http://dx.doi.org/10.1007/s10911-008-9107-3
33. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 2009; 15: 7479-91; PMID:20008848; http://dx.doi.org/10. 1158/1078-0432.CCR-09-0636
34. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2007; 18: 977-84
35. Glaser S, Demarest S, Miller BR, Hariharan K, Ho S, Dong J, et al. Compositions that Bind Multiple Epitopes of IGF-1R United States Patent Application 20090130105 2009
36. Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, et al. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 2010; 9: 2593-604; PMID:20716637; http://dx.doi.org/10.1158/1535-7163.MCT- 09-1018
37. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70: 588-97; PMID:20068188; http://dx.doi.org/10.1158/0008-5472.CAN-09-1417
38. Spangler JB, Manzari MT, Rosalia EK, Chen TF, Wittrup KD. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J Mol Biol 2012; 422: 532-44; PMID:22706026; http://dx.doi.org/10.1016/j. jmb.2012.06.014